UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000051464
Receipt number R000058678
Scientific Title PolyMyXin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine study (PMX-OPTIC study)
Date of disclosure of the study information 2023/06/27
Last modified on 2023/10/10 17:11:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

PolyMyXin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine study (PMX-OPTIC study)

Acronym

PMX-OPTIC study

Scientific Title

PolyMyXin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine study (PMX-OPTIC study)

Scientific Title:Acronym

PMX-OPTIC study

Region

Japan


Condition

Condition

Septic shock

Classification by specialty

Emergency medicine Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to investigate and analyze the maximum vasopressor dose administered before and after the initiation of Polymyxin B immobilized fiber column direct hemoperfusion (PMX-DHP, PMX), and examine its relationship with patient outcomes.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

28-day mortality rate

Key secondary outcomes

7-day survival rate
Length of hospital stay
Length of ICU stay
Duration of mechanical ventilation
CRP/Albumin/Lymphocyte count on the 14th day after ICU admission (closest to the 14th day based on blood samples collected between the 11th and 17th day)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients aged 18 years and older admitted to the ICU.
2. Patients treated with PMX for septic shock (diagnosed based on Sepsis-3 criteria).
3. Patients using vasopressor at the time of PMX initiation.
4. Patients who underwent their first PMX during the same hospitalization.

Key exclusion criteria

1. Cases of End of Life/Terminal Care where treatment was not the primary objective.
2. Patients who received interventions for circulatory support such as ECMO, VAD, IMPELLA (excluding IABP).

Target sample size

600


Research contact person

Name of lead principal investigator

1st name Yuji
Middle name
Last name Takahashi

Organization

Hitachi General Hospital

Division name

Department of Emergecy and Critical Care Medicine

Zip code

317-0077

Address

2-1-1, Jonancyo Hitachi, Ibaraki 317-0077, JAPAN

TEL

0294-23-1111

Email

yuji.mail@me.com


Public contact

Name of contact person

1st name Kensuke
Middle name
Last name Nakamura

Organization

Teikyo University

Division name

Department of Emergency Medicine

Zip code

178-8605

Address

2-11-1 Kaga, Itabashi-Ku, Tokyo 117-003, JAPAN

TEL

03-3964-1211

Homepage URL


Email

mamashockpapashock@yahoo.co.jp


Sponsor or person

Institute

Teikyo University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Teikyo University Ethical Review Board for Medical and Health Research Involving Human Subjects

Address

2-11-1 Kaga, Itabashi-Ku, Tokyo 117-003, JAPAN

Tel

03-3964-1211

Email

turb-office@teikyo-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 06 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2022 Year 05 Month 01 Day

Date of IRB

2022 Year 06 Month 13 Day

Anticipated trial start date

2022 Year 10 Month 01 Day

Last follow-up date

2023 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Data collection in progress


Management information

Registered date

2023 Year 06 Month 27 Day

Last modified on

2023 Year 10 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058678


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name